Radiation segmentectomy of hepatic metastases with Y-90 glass microspheres
Authors:
- 19 February 2021
- journal article
- research article
- Published by Springer Nature in Abdominal Radiology
- Vol. 46 (7) , 3428-3436
Abstract
Purpose To evaluate safety and efficacy of radiation segmentectomy (RS) with 90Y glass microspheres in patients with limited metastatic liver disease not amenable to resection or percutaneous ablation. Methods Patients with ≤ 3 tumors treated with RS from 6/2015 to 12/2017 were included. Target tumor radiation dose was > 190 Gy based on medical internal radiation dose (MIRD) dosimetry. Tumor response, local tumor progression (LTP), LTP-free survival (LTPFS) and disease progression rate in the treated segment were defined using Choi and RECIST 1.1 criteria. Toxicities were evaluated using modified SIR criteria. Results Ten patients with 14 tumors underwent 12 RS. Median tumor size was 3 cm (range 1.4–5.6). Median follow-up was 17.8 months (range 1.6–37.3). Response rates per Choi and RECIST 1.1 criteria were 8/8 (100%) and 4/9 (44%), respectively. Overall LTP rate was 3/14 (21%) during the study period. One-, two- and three-year LTPFS was 83%, 83% and 69%, respectively. Median LTPFS was not reached. Disease progression rate in the treated segment was 6/18 (33%). Median overall survival was 41.5 months (IQR 16.7–41.5). Median delivered tumor radiation dose was 293 Gy (range 163–1303). One major complication was recorded in a patient post-Whipple procedure who suffered anaphylactic reaction to prophylactic cefotetan and liver abscess in RS region 6.5 months post-RS. All patients were alive on last follow-up. Conclusion RS of ≤ 3 hepatic segments can safely provide a 2-year local tumor control rate of 83% in selected patients with limited metastatic liver disease and limited treatment options. Optimal dosimetry methodology requires further investigation.Keywords
Funding Information
- Memorial Sloan-Kettering Cancer Center (Cancer Support Grant P30 CA008748)
This publication has 40 references indexed in Scilit:
- Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect OutcomesClinical Colorectal Cancer, 2015
- Prevention and Management of Infectious Complications of Percutaneous InterventionsSeminars in Interventional Radiology, 2015
- Side Effects of Yttrium-90 RadioembolizationFrontiers in Oncology, 2014
- Superselective Yttrium-90 Radioembolization for Hepatocellular Carcinoma Yields High Response Rates with Minimal ToxicityJournal of Vascular and Interventional Radiology, 2014
- Unresectable Solitary Hepatocellular Carcinoma Not Amenable to Radiofrequency Ablation: Multicenter Radiology-Pathology Correlation and Survival of Radiation SegmentectomyHepatology, 2014
- Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinomaOncology Letters, 2013
- Research Reporting Standards for Radioembolization of Hepatic MalignanciesJournal of Vascular and Interventional Radiology, 2011
- Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of RadioembolizationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver MalignanciesJournal of Vascular and Interventional Radiology, 2006
- 90Y Microsphere (TheraSphere) Treatment for Unresectable Colorectal Cancer Metastases of the Liver: Response to Treatment at Targeted Doses of 135–150 Gy as Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomographic ImagingJournal of Vascular and Interventional Radiology, 2005